128 related articles for article (PubMed ID: 21751187)
1. Outcomes after prostate brachytherapy are even better than predicted.
Frank SJ; Levy LB; van Vulpen M; Crook J; Sylvester J; Grimm P; Pugh TJ; Swanson DA
Cancer; 2012 Feb; 118(3):839-47. PubMed ID: 21751187
[TBL] [Abstract][Full Text] [Related]
2. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy.
Frank SJ; Levy LB; Kuban DA; Lee AK; Kudchadker RJ; Bruno TL; van Vulpen M; Swanson DA
J Urol; 2009 Apr; 181(4):1658-63; discussion 1663-4. PubMed ID: 19233434
[TBL] [Abstract][Full Text] [Related]
3. PSA bounce after ¹²⁵I-brachytherapy for prostate cancer as a favorable prognosticator.
Engeler DS; Schwab C; Thöni AF; Hochreiter W; Prikler L; Suter S; Stucki P; Schiefer J; Plasswilm L; Schmid HP; Putora PM
Strahlenther Onkol; 2015 Oct; 191(10):787-91. PubMed ID: 26100965
[TBL] [Abstract][Full Text] [Related]
4. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
5. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence.
Mazeron R; Bajard A; Montbarbon X; Gassa F; Malet C; Rocher F; Clippe S; Bringeon G; Desmettre O; Pommier P
Radiat Oncol; 2012 Mar; 7():46. PubMed ID: 22449081
[TBL] [Abstract][Full Text] [Related]
6. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
7. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen bounce is related to overall survival in prostate brachytherapy.
Hinnen KA; Monninkhof EM; Battermann JJ; van Roermund JG; Frank SJ; van Vulpen M
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):883-8. PubMed ID: 21300477
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer.
Kattan MW; Potters L; Blasko JC; Beyer DC; Fearn P; Cavanagh W; Leibel S; Scardino PT
Urology; 2001 Sep; 58(3):393-9. PubMed ID: 11549487
[TBL] [Abstract][Full Text] [Related]
10. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
11. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce.
Das P; Chen MH; Valentine K; Lopes L; Cormack RA; Renshaw AA; Tempany CM; Kumar S; D'Amico AV
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):698-702. PubMed ID: 12377320
[TBL] [Abstract][Full Text] [Related]
12. Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'.
Ahmed KA; Davis BJ; Mynderse LA; Slezak JM; Bergstralh EJ; Wilson TM; Choo CR
Radiat Oncol; 2014 Jul; 9():171. PubMed ID: 25074478
[TBL] [Abstract][Full Text] [Related]
13. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.
Pickles T;
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1355-9. PubMed ID: 16406391
[TBL] [Abstract][Full Text] [Related]
15. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant.
Patel C; Elshaikh MA; Angermeier K; Ulchaker J; Klein EA; Chehade N; Wilkinson DA; Reddy CA; Ciezki JP
Urology; 2004 Jan; 63(1):110-3. PubMed ID: 14751360
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
Critz FA; Williams WH; Levinson AK; Benton JB; Schnell FJ; Holladay CT; Shrake PD
J Urol; 2003 Nov; 170(5):1864-7. PubMed ID: 14532794
[TBL] [Abstract][Full Text] [Related]
17. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
18.
Kindts I; Stellamans K; Billiet I; Pottel H; Lambrecht A
Strahlenther Onkol; 2017 Sep; 193(9):707-713. PubMed ID: 28488030
[TBL] [Abstract][Full Text] [Related]
19. Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
López-Torrecilla J; Boladeras A; Cabeza MA; Zapatero A; Jove J; Esteban LM; Henriquez I; Casaña M; González-San Segundo C; Gómez-Caamaño A; Mengual JL; Hervás A; Muñoz JL; Sanz G
Strahlenther Onkol; 2015 Oct; 191(10):792-800. PubMed ID: 26156249
[TBL] [Abstract][Full Text] [Related]
20. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.
Routman DM; Funk RK; Stish BJ; Mynderse LA; Wilson TM; McLaren R; Harmsen WS; Mara K; Deufel CL; Furutani KM; Haddock MG; Pisansky TM; Choo CR; Davis BJ
Brachytherapy; 2019; 18(1):1-7. PubMed ID: 30293836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
